Podcasts about Roche

Membership | Donations | Spotify | YouTube | Apple Podcasts | Discord | FB GroupThis week (actually, April) I speak with Rimma Boshernitsan (Website | LinkedIn), a speaker, interviewer, facilitator, and advisor who has partnered with senior leadership at Fortune 500 companies—including Google, Kaiser Permanente, Roche, TATA, and Aesop—guiding them through transformation and growth. Her writing has appeared in Fast Company, Inc. Magazine, Tech Crunch and Forbes.She began her career in management consulting at Deloitte, focusing on M&A and large-scale transformation, before moving into industry advising across healthcare, consumer business, and telecommunications. Later work in the art world taught her how cultural and political insights could drive innovation and transformation in business, leading her to found DIALOGUE in 2016.She now combines strategic foresight, human-centered innovation, and interdisciplinary thinking to help her clients reframe challenges, identify opportunities, and lead with intention. She sits on the board of trustees at Headlands Center for the Arts and on the SECA Council Board at SFMOMA, and is also an advisor to Stanford's Women in Design Program.Her most recent focus is in co-intelligence: integrating human, machine, and planetary intelligence to build future-facing organizations.I'm glad to have such an excellent partner in conversation to, as the Taoists say, “Feel our way across the river stone by stone” in a discussion about all of this and more: the re-emergence of nomadic populations and intentional communities, fumbling toward an idea of planetary culture, the role of intuition in leadership and biophilia in the design of our work spaces...it's a marvelously nondisciplinary co-exploration.There are well over a dozen episodes in the editing queue and founding members can access the entire trove of unedited conversations before they're released:✨ Show Links• Dig into nine years of mind-expanding conversations• Learn more about the Humans On The Loop project and its goals• Browse the books we discuss on the show at Bookshop.org• Contact me if you have a problem you think I can help you solve• Explore the interactive knowledge graph grown from over 250 episodes• Explore the Google Notebook for How To Live In The Future, my five-week science and philosophy course at Weirdosphere✨ Mentioned Media & PeopleIn Threads' dwindling engagement, social media's flawed hypothesis is laid bareIn a Time of Stress, Neuroaesthetic Spaces and Places Create a Path to Healing and HopeThe Triad of Intelligences: Harnessing Machine, Planetary, and Human Intuition in The Age of AIDIALOGUE Interviews: Ivy RossDIALOGUE Interviews: Susan MagsamenDIALOGUE Interviews: Kevin KellyMore Is Different: Broken symmetry and the nature of the hierarchical structure of scienceNikki SilvaBruce LiptonEd BernaysKen Wilber This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit michaelgarfield.substack.com/subscribe

Ecoutez les infos de ce dimanche 09 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 09 novembre à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 08 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 08 novembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 08 novembre à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 08 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ari Paparo and Eric Franchi are joined by Mathieu Roche, CEO of ID5, to discuss the recent acquisition of TrueData and its implications for the identity market. They explore the integration of identity graphs and IDs, the challenges of maintaining privacy and data security, and the evolving landscape of identity solutions. The conversation also touches on the importance of match rates, the role of identity in advertising, and the future of identity technology. Takeaways ID5's acquisition of TrueData aims to enhance identity solutions by integrating identity graphs with IDs. The acquisition increases ID5's staff and revenue by 30-40%, marking a significant expansion. ID5 focuses on making devices addressable and recognizable over time, enhancing match rates. TrueData specializes in connecting data at the user and household level, acting as a 'Rosetta Stone' for identity. The integration of ID5 and TrueData offers a unique end-to-end identity solution for clients. Identity is crucial for targeting, optimization, frequency capping, and measurement in advertising. The debate between deterministic and probabilistic identity solutions continues, with trade-offs in scale and precision. ID5's global presence and strong match rates provide a competitive edge in the identity market. The acquisition process involved extensive due diligence, highlighting the complexity of transatlantic deals. The future of identity technology involves balancing privacy concerns with the need for effective data solutions. Chapters 00:11 Introduction and Guest Welcome 03:42 ID5's Acquisition of TrueData 09:56 Identity Graphs and Device IDs 13:33 AI's Role in Advertising 29:49 The US Market and Global Scale 50:19 Deterministic vs. Probabilistic Solutions 57:23 Future of Identity in Ad Tech Learn more about your ad choices. Visit megaphone.fm/adchoices

Loic, Sylvain et Amélie discutent du livre Les Guerres de Lucas Tome 2 avec les auteurs Renaud Roche et Laurent Hopman. Star Wars en Direct est disponible sur les applications  Apple Podcast / Spotify / Amazon Music / Audible  / Deezer Venez rejoindre et participer à notre communauté d'auditeurs sur les plateformes Discord / Facebook / Twitter / Instagram Comme toujours, si vous avez suggestions ou réactions sur les sujets que nous venons de discuter, écrivez-nous un commentaire ci-dessous ou envoyez-nous un e-mail à studio@starwars.direct.

Ecoutez les infos de ce vendredi 07 novembre à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 07 novembre à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Nouveaux pilotes, un brin déjantés, à bord de la Libre Antenne sur RMC ! Jean-Christophe Drouet et Julien Cazarre prennent le relais. Après les grands matchs, quand la lumière reste allumée pour les vrais passionnés, place à la Libre Antenne : un espace à part, entre passion, humour et dérision, débats enflammés, franc-parler et second degré. Un rendez-vous nocturne à la Cazarre, où l'on parle foot bien sûr, mais aussi mauvaise foi, vannes, imitations et grands moments de radio imprévisibles !

Ecoutez les infos de ce jeudi 06 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

Ecoutez les infos de ce jeudi 06 novembre à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce jeudi 06 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

We sat down with Blaze Roche and Dfernado Zaremba and talked about their first Surf Film, MENTAL.

Ecoutez les infos de ce mercredi 05 novembre à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mercredi 05 novembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mercredi 05 novembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mercredi 05 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mercredi 05 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mercredi 05 novembre à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

Arsenal Need to Deal with the Title Race Storm Amid Fixture Chaos ft Art de Roche & Ed Aarons

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its launch two years ago. This move underscores the complex challenges in commercializing gene therapies, highlighting that even groundbreaking treatments can face hurdles in market penetration. It reflects broader implications for the commercialization strategies of innovative therapies and emphasizes that market acceptance is as crucial as clinical efficacy.In manufacturing and regulatory affairs, Regeneron is navigating hurdles with its Eylea HD due to persistent manufacturing issues. The FDA's complete response letter points to ongoing problems at a Novo Nordisk plant. This situation illustrates the critical role of manufacturing standards in securing regulatory approvals and ensuring consistent product availability. Regeneron's efforts to seek alternative manufacturing solutions emphasize the importance of compliance and quality assurance in the pharmaceutical landscape.Roche is advancing its kidney disease portfolio with a Phase 3 trial success for Gazyva against idiopathic nephrotic syndrome. Building on previous approvals for lupus nephritis, this achievement underscores Roche's strategic focus on expanding indications for existing biologics. It highlights the value of lifecycle management strategies in maximizing therapeutic potentials and extending the reach of established drugs.A significant shift in pharmacy benefit management is underway as Cigna's Evernorth division moves away from PBM rebates through Express Scripts. This transition towards a rebate-free model may influence industry-wide practices, addressing growing scrutiny over rebate structures criticized for their lack of transparency and their impact on drug pricing.CSL's decision to delay the spinoff of its flu vaccine unit amid declining U.S. immunization rates illustrates market challenges in vaccine uptake. The anticipated drop, particularly among older populations, raises public health concerns and underscores the necessity for enhanced outreach and education to improve immunization coverage.On the investment front, AbbVie, Regeneron, and Sanofi have collectively invested $80 million in ZAG Bio's Series A funding round. This company is developing thymus-targeted medicines for autoimmune diseases, reflecting continued interest in novel therapeutic approaches addressing unmet medical needs within the biotech space.Catalent's rebranding initiative signifies a strategic effort to align corporate identity with mission-driven objectives, emphasizing "missions that matter" as it approaches an anniversary milestone with Novo Nordisk's acquisition. Such rebranding efforts are critical for differentiating service offerings and reinforcing corporate values within competitive markets.The competitive landscape within diabetes and obesity treatment markets is experiencing a potential paradigm shift following the results from Innovent and Eli Lilly's Phase 3 trial of mazdutide. This dual GLP-1/glucagon receptor agonist outperformed Novo Nordisk's semaglutide, offering improved outcomes in weight reduction and glycemic control. Mazdutide's dual mechanism could redefine treatment protocols, offering patients enhanced therapeutic benefits.MapLight Therapeutics has successfully raised $250 million through an IPO to advance its schizophrenia treatment candidate, Cobenfy. This funding supports further clinical development and potential commercialization efforts, reflecting investor confidence in innovative neurologSupport the show

Sylke Poehling didn't set out to lead one of the world's most advanced gene therapy companies - but a love for drug discovery and a career built on curiosity, courage and conviction brought her there.  Now CEO of Spark Therapeutics and SVP at Roche, Sylke joins us on Careers in Discovery to share her journey from academia into Biotech, how Spark pioneered the world's first FDA-approved directly administered gene therapy, and what it means to build the next generation of treatments - and the company culture to deliver them.  She reflects on what it takes to lead through risk and uncertainty, how to balance scientific ambition with operational focus, and why authenticity and clarity are at the heart of impactful leadership.  An inspiring conversation with a scientist-turned-CEO who's still pushing boundaries and redefining what's possible in genetic medicine. 

Auf dem Roche-Areal an der Grenzacherstrasse im Kleinbasel wurde heute der Grundstein für einen weiteren Bau gelegt, für den Bau 12. Das Forschungsgebäude wird 72 Meter hoch und hat 15 Stockwerke. Die Verantwortlichen betonen, es sei ein Bekenntnis zum Standort Basel. Ausserdem: - Basel-Stadt nimmt diskussionslos Kinder aus Gaza auf - Auf Schatzsuche im historischen Museum - Fasnacht in Lörrach gerettet

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

John Duggan and Johnny Ward are back for another episode of the Racing Pod and this week they are joined by jockey and current leading rider in the William Hill Each Way Extra Challenge Series, Tiernan Power Roche who spoke about his role model jockey's and his future ambitions in his career. The Racing Pod on Off The Ball is brought to you by William Hill. 18 + see gamblingcare.ie

In der heutigen Folge sprechen die Finanzjournalistinnen Anja Ettel und Lea Oetjen über den Aktientausch zweier einstiger Biotech-Rivalen, die Begnadigung des reichsten US-Häftlings und den Government Shutdown, der zum Risiko für die Amerikaner wird. Außerdem geht es um SAP, Tesla, Chevron, Exxon, Siemens Energy, Deutsche Telekom, T-Mobile, MTU, Beiersdorf, Unilever, Roche, Atoss, Lukoil, Rosneft, Rivian, Biontech, Curevac, Moderna, Bristol Myers Squibb, BlackRock, Solana, Gold, Bitcoin, Ethereum. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Why do Chief People Officers need strong networks — and how can you build one that truly supports you?In this episode of HR Coffee Time, host Fay Wallis is joined by Nebel Crowhurst, who's featured on the HR Most Influential list several years running and has held senior roles with Virgin, River Island, Roche, and Reward Gateway.Nebel talks about the realities of being a CPO — the highs, the pressures, and how she protects her wellbeing — along with brilliant advice on building your own community of support (even if you find networking uncomfortable).In this episode, you'll learn:The key differences between being an HR Director and a Chief People Officer.How to protect your boundaries and wellbeing in a demanding role.What it means to be a business leader, not just a functional one.How to reframe networking into “building your community.”Practical tips for creating and nurturing a supportive network.Nebel also explains her move into fractional CPO work, what it involves, and why this model is becoming increasingly popular in growing organisations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broader industry trends where companies reassess their operational strategies for greater efficiency. While this decision may impact the local workforce and supply chain dynamics, it underscores a wider reevaluation within the industry regarding sourcing strategies and optimizing production capabilities.Turning to regulatory news, Amgen and AstraZeneca have achieved a notable milestone with Tezspire, which has received approval for a second indication in both the U.S. and Europe. This success highlights the strategic importance of expanding drug indications to maximize therapeutic potential and market reach. The approval also reflects a trend where robust clinical data supports regulatory endorsements across various regions, enhancing the global footprint of pharmaceutical innovations.In manufacturing developments, Galderma is making headlines with a $650 million investment in U.S.-based production facilities for Nemluvio. This commitment to domestic manufacturing aligns with industry-wide movements towards reshoring production to bolster supply chain resilience. As demand for dermatological products increases, enhancing local infrastructure promises not only to meet market needs but also to secure supply stability in uncertain times.Meanwhile, Moderna's recent decision to discontinue its congenital cytomegalovirus vaccine program after disappointing Phase 3 results illustrates the inherent uncertainties present in vaccine development. Despite extensive efforts, the vaccine did not demonstrate sufficient efficacy in preventing CMV infections among women. This outcome serves as a reminder of the critical role that robust clinical trial data plays in guiding strategic decisions within pharmaceutical pipelines. While mRNA technology has seen success against COVID-19, this setback highlights complexities involved when tackling other viral pathogens, potentially redirecting Moderna's focus towards more promising candidates.Roche is navigating through challenges such as currency fluctuations and slower-than-expected pharmaceutical sales in its third quarter. Despite these headwinds, Roche projects confidence in its long-term growth strategies, showcasing resilience through its diversified portfolio. Furthermore, Roche's decision to discontinue five Chugai solid tumor assets reflects broader industry movements towards reassessment and realignment within pipelines. Such decisions often emerge from early-phase trials failing to meet expected outcomes or shifts towards areas with greater promise, enabling companies like Roche to streamline resources towards more viable therapeutic areas.Compliance remains under scrutiny at Nephron Pharmaceuticals as ongoing FDA issues emphasize the necessity of maintaining stringent quality standards throughout manufacturing processes. Such regulatory challenges highlight the criticality of ensuring product safety and efficacy within the industry.On the technological front, the integration of artificial intelligence into life sciences commercialization is transforming industry landscapes. Though many organizations are still catching up with this digital shift, those that have embraced AI are experiencing significant improvements in efficiency and patient engagement. As companies continue embedding AI into their strategic frameworks, these initiatives promise to redefine operational paradigms and open new paths for growth.The landscape remains dynaSupport the show

Ever tried to escape work by picking up a hobby, only to discover it teaches you everything about your profession? In this fascinating conversation with Philip Atkinson, author of "BeeWise: 12 Leadership Lessons from Inside a Busy Hive," Cam and Otis explore how the complex world of beekeeping offers surprising insights into organizational leadership."I was looking in my private life to start a new hobby to do nothing to do with work," Philip explains about his beekeeping journey. "And it was all about complex organizations and decision making and communication and what the bees do. And of course, bang, it hit me. Beekeeping is a metaphor for complex life in working organizations today."From seasonal cycles that mirror business planning to colony division that reflects organizational scaling, Philip draws powerful parallels between the busy hive and today's workplace. "The bees have a natural survival instinct, and they need to adapt and grow," he shares, explaining how this translates to leadership challenges. "As a single leader, I can't do everything. I actually need to create an environment to scale things by trusting other people to be great."Whether you're fascinated by nature, looking for fresh leadership perspectives, or simply curious about how a hobby can transform into a life's purpose, this conversation offers rich insights into what we can learn from these remarkable creatures—or, as Philip would say, Apis Melifera.More About Philip:Philip Atkinson is a leadership coach, organizational transformation expert, and founder of Hive-Logic. With leadership roles at Novartis, Roche, Sanofi, and Publicis, Philip has worked with some of the world's largest organizations to build stronger teams and healthier cultures. Based near the Swiss border in France, he supports senior leaders across Europe and beyond through coaching, facilitation, and strategy. His warm, thought-provoking communication style has landed him features in Forbes, Management Today, CEO World, and BBC TV and radio. Philip is also a beekeeper. In his book Bee Wise: 12 Leadership Lessons from a Busy Beehive, he draws powerful insights from the hidden workings of the hive. The book explores decision-making, inclusion, communication, and purpose with contributions from global thought leaders at EY, L'Oréal, and more. All profits support Bees for Development, a charity helping families build sustainable livelihoods through beekeeping.#LeadershipLessons #BeekeepingAndBusiness #OrganizationalWisdom #HiveLogic #AdaptiveLeadership #Teamwork #NatureInspiredLeadership #LeadershipDevelopment #TribeAndPurpose #10xYourTeamChapter Times and Titles:From Corporate Life to Beekeeping [00:00 - 05:00]Introduction to Philip Atkinson and "BeeWise"The search for a hobby, "nothing to do with work"The moment of realization: "Beekeeping is a metaphor"Apis Melifera: More Than Just Bees [05:01 - 10:00]The fascinating terminology of beekeepingHow the beekeeping community responded to Philip's insightsInitial connections between hives and organizationsSeasonal Wisdom from the Hive [10:01 - 20:00]"Close some of the other projects first" - lessons in prioritizationThe bee lifecycle and seasonal changesHow nature's patterns inform business planningColony Division: A Model for Scaling [20:01 - 35:00]"The bees have a natural survival instinct."How colonies grow by dividing and multiplyingParallels to organizational growth and leadershipCreating an Environment for Others to Thrive [35:01 - 45:00]"As a single leader, I can't do everything."Trusting others to be greatBuilding systems that scale beyond individual capacityThe Busy Hive as Leadership Metaphor [45:01 - End]Key takeaways from Philip's bookHow to connect with Hive-LogicFinal thoughts on learning from nature

From our first breath, the air we breathe and our genes shape how our lungs function. It's a complex interplay we began exploring in our season four episode “Take A Deep Breath: Treating Asthma.” Today, we're branching out to discuss lung biology and the diseases that make it difficult to breathe. In this episode, co-host Maria Wilson speaks with Dorothy Cheung, Executive Group Medical Director, and Daniel Lafkas, Senior Principal Scientist, Translational Discovery Research, Roche, to understand how conditions with unmet need like chronic bronchitis and emphysema disrupt lung function. They discuss the challenges to treating lung diseases and explore promising approaches, from cutting-edge imaging technologies that help researchers uncover early drivers of disease, to treatments aimed at stopping the loss of lung function and restoring it. Read the full text transcript at www.gene.com/stories/decoding-lung-disease

Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes  What if, instead of giving your team answers, you asked the right questions and listened? In this episode, Kevin sits down with Luciana Núñez to discuss how coaching can be more than just a skill; it can be a leadership philosophy that transforms individuals, teams, and entire organizations. Luciana shares why the command-and-control leadership model no longer works in today's world, and how leading with coaching creates alignment, trust, and engagement. They dive into key concepts from her book, including the “performance equation” (P = C × A²), the power of visualization, and the importance of overcoming biases as a leader. Luciana offers practical insights on how leaders can develop active listening skills, ask powerful questions, and foster greater accountability and resilience in their teams. Listen For 00:00 Introduction: Leading with coaching 01:58 Guest introduction Luciana Nunez 03:05 Luciana's journey from Argentina to executive coaching 05:16 Discovering the power of coaching 05:33 Why Luciana and Tom Preston wrote Coaching Power 07:10 The writing and collaboration process 08:20 Case studies and structure of the book 09:18 Leading with coaching vs being a coach 10:19 Why command and control leadership no longer works 11:24 Listening and asking powerful questions 13:33 The mindset shift from manager to leader 15:09 Checking your biases as a leader 17:06 Staying curious and self aware while coaching 19:11 Helping others visualize success 21:22 Neuroscience and practice of visualization 24:03 The performance equation P = C × A² 26:39 Why attitude is limitless 27:34 Coaching remotely or at a distance 29:30 Creating safety and context in virtual coaching 31:35 Getting to know Luciana personally 33:05 What Luciana is reading The Boiling Frog 35:20 Where to find Luciana and her work 37:38 Wrap up and outro Luciana's Story: Luciana Núñez, co-author of Coaching Power: Lead with Coaching to Create Individual, Team, and Organizational Outperformance, with Tom Preston. She is a partner and Head of Americas at The Preston Associates, one of the world's premier executive coaching firms. An accomplished executive coach and former CEO with more than 20 years of leadership experience at Fortune 500 companies, including Bayer, Danone, and Roche, she blends her strategic expertise with a passion for mentoring, serving as a board member, investor, and advisor to entrepreneurs and executives worldwide. Having lived and worked in multiple continents, Luciana thrives in diverse cross-cultural contexts. She is a Sommelière, an art lover and annual competitor in Spartan obstacle course endurance races. This Episode is brought to you by... Flexible Leadership is every leader's guide to greater success in a world of increasing complexity and chaos.  Book Recommendations Coaching Power: Leading With Coaching to Create Individual, Team, and Organizational Outperformance by Tom Preston and Luciana Nunez  THE BOILING FROG: 21 STRATEGIES TO TRANSFORM STRESS INTO STRENGTH & COMFORT by Ash Kumar MD Like this? The Coaching Effect with Bill Eckstrom How to Deliver Bad News - and Get Away With it! with Mahesh Guruswamy Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group  

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.